Clinical trial • Phase I • Oncology
Clinical trial in Advanced solid tumors with MET genetic alterations
Phase I trial for Advanced solid tumors with MET genetic alterations. 68 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced solid tumors with MET genetic alterations
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 26-04-2024
- First CTIS Authorization Date
- 05-07-2024
Trial design
Phase I trial across 4 sites in France.
- Biomarker Stratified
- True, biomarker: MET genetic alterations
- Target Sample Size
- 68
Eligibility
Recruits 68 Vulnerable population not selected (isVulnerablePopulationSelected: false). No consent or assent details provided..
- Vulnerable Population
- Vulnerable population not selected (isVulnerablePopulationSelected: false). No consent or assent details provided.
Recruitment
- Planned Sample Size
- 68
- Recruitment Window Months
- 90
Geography
- Total Number Of Sites
- 4
- Total Number Of Participants
- 68
France
- Earliest CTIS Part Ii Submission Date
- 12-03-2024
- Latest Decision Or Authorization Date
- 21-10-2025
- Processing Time Days
- 588
- Number Of Sites
- 4
- Number Of Participants
- 14
Sites
- Site Name
- Centre Hospitalier Universitaire Grenoble Alpes
- Department Name
- Pneumology and Physiology Unit
- Principal Investigator Name
- Denis Moro-Sibilot
- Principal Investigator Email
- dmoro-sibilot@chu-grenoble.fr
- Contact Person Name
- Denis Moro-Sibilot
- Contact Person Email
- dmoro-sibilot@chu-grenoble.fr
- Site Name
- Unite De Recherche Clinique HIA Begin
- Department Name
- Clinical Research Unit
- Principal Investigator Name
- Carole Helissey
- Principal Investigator Email
- carole.helissey@gmail.com
- Contact Person Name
- Carole Helissey
- Contact Person Email
- carole.helissey@gmail.com
- Site Name
- Institut Gustave Roussy
- Department Name
- Médecine Oncologique
- Principal Investigator Name
- Benjamin Besse
- Principal Investigator Email
- benjamin.besse@gustaveroussy.fr
- Contact Person Name
- Benjamin Besse
- Contact Person Email
- benjamin.besse@gustaveroussy.fr
- Site Name
- Centre Leon Berard
- Department Name
- Medical Oncology
- Principal Investigator Name
- Philippe Cassier
- Principal Investigator Email
- philippe.cassier@lyon.unicancer.fr
- Contact Person Name
- Philippe Cassier
- Contact Person Email
- philippe.cassier@lyon.unicancer.fr
Sponsor
Primary sponsor
- Full Name
- Turning Point Therapeutics Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Contract research organisations
- Name
- Bristol Myers Squibb International Corporation
- Responsibilities
- GSM-CT public/scientific contact (functional contact listed in sponsor public and scientific contacts)
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)